AD/PD™ 2026
March 17-21, 2025 | Copenhagen, Denmark
FIVE CRITICAL INFLECTION POINTS IN ALZHEIMER’S: GUIDEPOSTS FOR SMARTER DRUG DEVELOPMENT
Bart De Strooper (Belgium)
INNATE IMMUNITY AS TREATMENT TARGET IN ALZHEIMER’S DISEASE
Michael Heneka (Luxembourg)
UNDERSTANDING NEURODEGENERATIVE DISEASES TODAY: LESSONS FROM CLINICOPATHOLOGICAL CORRELATIONS AND THE ONGOING ROLE OF NEUROPATHOLOGY IN THE BIOMARKER AGE
Lea Grinberg (USA)
KEY SLEEP ISSUES PERTINENT TO THE DEVELOPMENT AND PROGRESSION OF NEURODEGENERATION IN LEWY BODY DISEASE AND RELATED DISORDERS
Bradley Boeve (USA)
THE ROLE OF PERIPHERAL INFLAMMATION IN NEURODEGENERATIVE DISEASE: WHO LET THE DOGS OUT
Malu Tansey (USA)
FROM CELL ATLASES TO MEDICINES, WITH AI
Aviv Regev (USA)
AD/PD™ 2025
April 1-5, 2025 | Vienna, Austria
PIVOTAL POINTS IN PREVENTION TRIALS AND THE NEW ERA OF PRECISION MEDICINE FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS
Miia Kivipelto (Sweden)
PLASMA BIOMARKERS FOR DEMENTIAS IN THE ERA OF DISEASE MODIFYING THERAPIES
Charlotte Theunissen (The Netherlands)
PATHOGENIC MECHANISMS OF FAMILIAL AD AND EMERGING THERAPEUTIC DEVELOPMENTS
Jie Shen (USA)
THE ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE: OBSERVATIONS AND IMPLICATIONS
Jeff Cummings (USA)
TREATMENT OF DLB AND PDD: STATUS AND NEW DEVELOPMENTS
Dag Aarsland (UK)
GLP-1R AGONIST EFFECTS IN BRAIN
Lotte Bjerre Knudsen (Denmark)
AD/PD™ 2024
March 5-9, 2024 | Lisbon, Portugal
TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS FOR ALZHEIMER’S DISEASE
Howard Fillit (USA)
DON PRICE MEMORIAL LECTURE:CRYO-EM STRUCTURES OF DISEASE FILAMENTS FROM HUMAN BRAINS
Michel Goedert (UK)
THE GENETICS OF NEURODEGENERATIVE DISEASES – FROM RARE POPULATIONS TO COMMON VARIANTS
Rita Guerreiro (USA)
ESCAPING DEMENTIA UNTIL EXTREME AGES: WHAT CAN COGNITIVELY HEALTHY CENTENARIANS TEACH US?
Henne Holstege (The Netherlands)
A BIOLOGIC DEFINITION AND STAGING PLATFORM FOR NEURONAL SYNUCLEIN DISEASE
Ken Marek (USA)
ERIC N. BIRCH MEMORIAL LECTURE: SYNERGY IN SCIENCE: LEVERAGING WHAT WE’VE LEARNED ABOUT PD AND AD TO INFORM LEWY BODY DEMENTIA RESEARCH AND THERAPEUTIC DEVELOPMENT
Pamela McLean (USA)
MS TECHNOLOGIES FOR PLASMA BIOMARKER DEVELOPMENT
Koichi Tanaka (Japan)
AD/PD™ 2023
March 28 – April 1, 2023 | Gothenburg, Sweden
NEXT GENERATION RNA BASED THERAPEUTICS
Ada Yonath (Israel)
THE FUTURE OF PD THERAPY; WHY MULTI TARGET DRUGS
Moussa Youdim (Israel)
CSF AND BLOOD BIOMARKERS FOR AD – PATHOPHYSIOLOGY, DIAGNOSTIC ALGORITHMS AND THERAPY MONITORING
Kaj Blennow (Sweden)
TRANSLATIONAL NEUROPATHOLOGY: BEGINNING AT THE END TO INFORM THE BEGINNING
Melissa Murray (USA)
CONSIDERATION OF BLOOD-BASED BIOMARKERS FOR COMMUNITY SCREENING – INFLUENCE OF COMORBIDITIES, RACE/ETHNICITY, AND SEX
Michelle Mielke (USA)
DISEASE MODIFIERS FOR ALZHEIMER’S DISEASE – A REGULATORY PERSPECTIVE
Yaning Wang (USA)
THE FIRST DISEASE-MODIFYING TREATMENTS FOR AD: A GLASS HALF FULL
Denis Selkoe (USA)
AD/PD™ 2022
March 15-20, 2022 | Barcelona, Spain
REGULATION OF SYNAPTIC FUNCTION BY ALZHEIMER’S ASSOCIATED GENES
Thomas Sudhof (USA)
FLUID AND PET IMAGING BIOMARKERS FOR ALZHEIMER’S AND PARKINSON’S DISEASES
Oskar Hansson (Sweden)
KEY MILESTONES IN ALZHEIMER’S DISEASE
Samantha Budd-Haeberlein (USA)
DISEASE MODIFICATION IN PD: WHAT ARE THE PROMISING TARGETS?
Anthony Lang (Canada)
TAU AND DIVERSITY OF DRIVERS IN ALZHEIMER DISEASE
Bradley Hyman (USA)
MICROGLIAL TAM RECEPTORS IN ALZHEIMER’S DISEASE
Greg Lemke (USA)
STOMPING OUT THE SPARK: TARGETING PYROGLU3 AMYLOID-BETA FOR THE TREATMENT OF ALZHEIMER’S DISEASE
Cynthia Lemere (USA)
AD/PD™ 2021
March 9-14, 2021 | Virtual Conference
THE UNIFYING ROLE OF INNATE IMMUNITY IN THE ETIOLOGY AND PATHOGENESIS OF ALZHEIMER’S DISEASE
Rudolph Tanzi (USA)
UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER’S PATHOLOGY
Teresa Gomez Isla (USA)
MONOCLONAL ANTIBODIES TARGETING AMYLOID BETA FOR THE POTENTIAL TREATMENT OF ALZHEIMER’S DISEASE
Roger Nitsch (Switzerland)
APOE AND TREM2: ZOOMING IN ON CONVERGING MICROGLIAL RESPONSES IN ALZHEIMER’S DISEASE
Guojun Bu (USA)
NEW INITIATIVES IN DRUG DEVELOPMENT FOR ALS
Angela Genge (Canada)
NONINVASIVE SENSORY STIMULATION TO TREAT ALZHEIMER’S DISEASE
Li-Huei Tsai (USA)
AD/PD™ 2019
March 26-31, 2019 | Lisbon, Portugal
TREM2 – FROM BASIC MECHANISMS TO HUMAN PATIENTS
Christian Haass (Germany)
HOW MICROGLIA WIRE AND UNWIRE THE BRAIN
Beth Stevens (USA)
WHAT WORKS AND DOESN’T WORK IN AD
Rachelle Doody (Switzerland)
ROLE OF ALPHA-SYNUCLEIN AND LESSONS LEARNED FROM THE BRAIN
Glenda Halliday (Australia)
THE CELL BIOLOGY OF SYNAPSE FORMATION AND SYNAPSE DEGENERATION
Thomas Sudhof (USA)
MODULATION OF Ab DEPOSITION BY THE MICROBIOME
Sangram Sisodia (USA)
BIOMARKER ACTIVITIES IN α-SYNUCLEIN AGGREGATION DISORDERS
Brit Mollenhauer (Germany)
AAT-AD/PD™ 2020 – 2-5 April, 2020 | Virtual Meeting
AAT-AD/PD™ 2018 – 15-18 March, 2018 | Torino, Italy
AD/PD™ 2017 – March 29 – April 2, 2017 | Vienna, Austria
AD/PD™ 2015 – March 18-22, 2015 | Nice, France
AD/PD™ 2013 – March 6-10, 2013 | Florence, Italy
AD/PD™ 2011 – March 9-13, 2011 | Barcelona, Spain
AD/PD™ 2009 – March 11-15, 2009 | Prague, Czech Republic
AD/PD™ 2007 – March 14-18, 2007 | Salzburg, Austria
AD/PD™ 2005 – March 9-13, 2005 | Sorrento, Italy
AD/PD™ 2003 – May 8-12, 2003 | Seville, Spain
AD/PD™ 2001 – March 31 – April 5, 2001 | Kyoto, Japan
AD/PD™ 1997 – May 18-23 | Eilat, Israel
AD/PD™ 1993 – November 1-6 | Chicago, Illinois, USA
AD/PD™ 1993 – November 6-10 | Kyoto, Japan
AD/PD™ 1985 – March 24-27 | Eilat, Israel